Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADIOS in mild to moderate COVID-19
NCT05552625Phase 3Withdrawn
- Sponsor
- Helixmith
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing TADIOS + Standard of care with Placebo + Standard of care (2 arms). Primary endpoints: Evaluation of antioxidative and inflammatory Biomarkers at Day 14, Ordinal Scale for COVID-19 Assessment at Day 14 and 5 more. Planned start May 2021; status: withdrawn.
02
Drugs
dandelion
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05552625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552625.